Clinical Research Directory
Browse clinical research sites, groups, and studies.
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
Sponsor: Chinese Academy of Medical Sciences
Summary
Currently, adjuvant therapy is not recommended for patients with esophageal squamous cell carcinoma who received radical surgery. However, the recurrence rate is as high as 23.8%-58%, and the median time-to-recurrence is about 10.5 months. In patients who had residual tumor after surgery, evidence lacks for chemoradiation. The aim of the study is to evaluate the efficacy and safety of chemoradiation therapy in patients with recurrences after radical surgery or palliative surgery.
Official title: Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients: A Prospective, Multicenter Clinical Trial
Key Details
Gender
All
Age Range
16 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2018-11-01
Completion Date
2027-10-31
Last Updated
2018-12-12
Healthy Volunteers
No
Conditions
Interventions
Involved field irradiation
Involved field irradiation; intensity-modulated radiation therapy
Elective field irradiation
Elective field irradiation; intensity-modulated radiation therapy
Paclitaxel
Paclitaxel 135-150mg/m2, d1, every 3 weeks
Platinum
for lobaplatin, 30mg/m2, d1-2, total dose should not exceed 50mg,every 3 weeks; for nedaplatin 50mg/m2, d1-2, every 3 weeks;
PEG-rhG-CSF
PEG-rhG-CSF 3-6mg, 48 hours after chemotherapy
Locations (1)
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Beijing, Beijing Municipality, China